A tubulin binding molecule drives differentiation of acute myeloid leukemia cells

[1]  D. Noh,et al.  JAK2 regulates paclitaxel resistance in triple negative breast cancers , 2021, Journal of Molecular Medicine.

[2]  Xiaomei Ma,et al.  CPEB4-Promoted Paclitaxel Resistance in Ovarian Cancer In Vitro Relies on Translational Regulation of CSAG2 , 2021, Frontiers in Pharmacology.

[3]  P. Vyas,et al.  New directions for emerging therapies in acute myeloid leukemia: the next chapter , 2020, Blood Cancer Journal.

[4]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[5]  Erinna F. Lee,et al.  A small molecule interacts with VDAC2 to block mouse BAK-driven apoptosis , 2019, Nature Chemical Biology.

[6]  D. Dill,et al.  Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index , 2019, Scientific Reports.

[7]  D. Barash,et al.  Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types , 2019, npj Precision Oncology.

[8]  R. Collins,et al.  Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia , 2019, Leukemia.

[9]  I. Flinn,et al.  Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. , 2019, Blood.

[10]  Gordon K Smyth,et al.  The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads , 2018, bioRxiv.

[11]  Youli Xiao,et al.  Chemoproteomics Reveals the Antiproliferative Potential of Parkinson's Disease Kinase Inhibitor LRRK2-IN-1 by Targeting PCNA Protein. , 2018, Molecular pharmaceutics.

[12]  P. Vyas,et al.  Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib , 2018, Nature Medicine.

[13]  R. Collins,et al.  Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.

[14]  A. Letai,et al.  Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.

[15]  Esther S. Kim,et al.  Enasidenib: First Global Approval , 2017, Drugs.

[16]  P. Vyas,et al.  Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. , 2017, Blood.

[17]  M. Prunotto,et al.  Opportunities and challenges in phenotypic drug discovery: an industry perspective , 2017, Nature Reviews Drug Discovery.

[18]  Howard Y. Chang,et al.  Lineage-specific and single cell chromatin accessibility charts human hematopoiesis and leukemia evolution , 2016, Nature Genetics.

[19]  Quentin Giai Gianetto,et al.  Uses and misuses of the fudge factor in quantitative discovery proteomics , 2016, Proteomics.

[20]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[21]  Alexander Dobin,et al.  Mapping RNA‐seq Reads with STAR , 2015, Current protocols in bioinformatics.

[22]  M. Tallman,et al.  Acute promyelocytic leukemia: where did we start, where are we now, and the future , 2015, Blood Cancer Journal.

[23]  M. Dallman,et al.  Multifunctional Reagents for Quantitative Proteome-Wide Analysis of Protein Modification in Human Cells and Dynamic Profiling of Protein Lipidation During Vertebrate Development** , 2015, Angewandte Chemie.

[24]  Thomas Sander,et al.  DataWarrior: An Open-Source Program For Chemistry Aware Data Visualization And Analysis , 2015, J. Chem. Inf. Model..

[25]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[26]  D. Swinney,et al.  The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines , 2013, Journal of biomolecular screening.

[27]  S. Sze,et al.  Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling. , 2013, Angewandte Chemie.

[28]  P. Iversen,et al.  Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. , 2013, Blood.

[29]  S. Zahler,et al.  Pretubulysin derived probes as novel tools for monitoring the microtubule network via activity-based protein profiling and fluorescence microscopy. , 2012, Molecular bioSystems.

[30]  Martin Dugas,et al.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia , 2012, Nature Medicine.

[31]  Shao Q Yao,et al.  Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes. , 2012, Journal of the American Chemical Society.

[32]  Delany Rodriguez,et al.  Design and synthesis of a new class of membrane-permeable triazaborolopyridinium fluorescent probes. , 2011, Journal of the American Chemical Society.

[33]  P. Zipfel,et al.  Factor H and Factor H-Related Protein 1 Bind to Human Neutrophils via Complement Receptor 3, Mediate Attachment to Candida albicans, and Enhance Neutrophil Antimicrobial Activity , 2009, The Journal of Immunology.

[34]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[35]  M. Mann,et al.  Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. , 2003, Analytical chemistry.

[36]  Janet S. Lee,et al.  Mechanisms of action of arsenic trioxide. , 2002, Cancer research.

[37]  R. Discipio,et al.  Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). , 1998, Journal of immunology.

[38]  D. Sheer,et al.  Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. , 1990, Science.

[39]  M. Minden,et al.  Expression of a retinoic acid receptor gene in myeloid leukemia cells. , 1989, Leukemia.

[40]  K. Kanematsu,et al.  Novel Bicycloannulation via Tandem Vinylation and Intramolecular Diels-Alder Reaction of Five-Membered Heterocycles. , 1984 .

[41]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[42]  John M. Walker,et al.  Myeloid Leukemia , 2020, Methods In Molecular Medicine™.

[43]  C. E. Field.  Myeloid Leukaemia. , 1939, Proceedings of the Royal Society of Medicine.